Description
“ Estrogen Receptor Positive ( ER +) Breast Cancer - Treatment Landscape & Competitive Analysis , 2016 ”, report provides comprehensive insights about the treatment landscape across this indication . This report also provides the deep understanding of the stages of the Estrogen Receptor Positive ( ER +) Breast Cancer , epidemiology , risk factors , diagnosis etc . A key objective of the report is to establish the understanding of the treatment landscape and competitive analysis of the Estrogen Receptor Positive ( ER +) Breast Cancer which mainly describes the treatment of breast cancer at different stages . Breast cancer is the condition where the cells of the breast area become tumorous , that is , they undergo unlimited cell division . Both women and men are affected but chances of men being diagnosed with breast cancer are rare . Each year about 2,300 new cases of breast cancer in men and about 230,000 new cases in women are diagnosed . It is the second most common cancer among women in USA .
Request a sample of this report @ http :// www . orbisresearch . com / contacts / request-sample / 209353 .
This report provides the insights of the marketed drugs for the Estrogen Receptor Positive ( ER +) Breast Cancer which includes the Targeted Therapy , Hormone Therapy and Chemotherapy . In case of Estrogen Receptor Positive ( ER +) Breast Cancer , Hormone therapy is the main focus of treatment after surgery and chemotherapy . Hormonal therapy is usually recommended after 5 years of surgery and can be divided into Estrogen blocking hormonal therapy and estrogen lowering hormonal therapy based on the mechanism of action of the hormonal therapy drugs . Of all the late-stage pipeline drugs , Buparlisib is expected to reach the market in the next few years .
Purchase a copy of this report @ http :// www . orbisresearch . com / contact / purchase / 209353 . For more information contact sales @ orbisresearch . com
Recent report of covers the treatment landscape which provides the treatment options by different stages and type of the breast cancer . There are four chemotherapy drugs , six hormone therapy drugs and one targeted therapy drugs in market for the treatment of Estrogen Receptor Positive ( ER +) Breast Cancer .
Report Highlights :
• The new report , provides a Estrogen Receptor Positive ( ER +) Breast Cancer Treatment Landscape across the globe
• The report provides profiles of the marketed drug which includes the product description , cost of treatment , development partner , patent expiry date , sales data etc .
• Comparative analysis of marketed drugs by therapy , cost of treatment , Therapeutic Class . Coverage of the Estrogen Receptor Positive ( ER +) Breast Cancer Phase III and Pre-registration Drugs Analysis by product type , molecule type , route of administration , Median Progression Free Survival
www . orbisresearch . com ; + 1 ( 214 ) 884-6817 ; + 9120-64101019